ArticleCurrent oncology (Toronto, Ont.)2026

Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.

Lu Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.